• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

白细胞介素 7 免疫疗法与重症 2019 冠状病毒病（COVID-19）患者淋巴细胞计数的关联。

Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19).

机构信息

Department of Critical Care Medicine, Saint Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.

Intensive Care Unit Department and Inserm Centre Investigation Clinique 1435 and Unité Mixte de Recherche 1092, University Hospital of Limoges, Limoges, France.

出版信息

JAMA Netw Open. 2020 Jul 1;3(7):e2016485. doi: 10.1001/jamanetworkopen.2020.16485.

DOI:10.1001/jamanetworkopen.2020.16485
PMID:32697322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7376391/
Abstract

This case series examines whether interleukin 7 (IL-7) is associated with restored host protective immunity in patients with severe coronavirus disease 2019 (COVID-19) and immunosuppression.

摘要

本病例系列研究探讨了白细胞介素 7（IL-7）是否与重症 2019 冠状病毒病（COVID-19）和免疫抑制患者中宿主保护性免疫的恢复有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e82c/7376391/6a1fbd59ae8f/jamanetwopen-3-e2016485-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e82c/7376391/6a1fbd59ae8f/jamanetwopen-3-e2016485-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e82c/7376391/6a1fbd59ae8f/jamanetwopen-3-e2016485-g001.jpg

相似文献

1
Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19).白细胞介素 7 免疫疗法与重症 2019 冠状病毒病（COVID-19）患者淋巴细胞计数的关联。
JAMA Netw Open. 2020 Jul 1;3(7):e2016485. doi: 10.1001/jamanetworkopen.2020.16485.
2
Lymphopenia in COVID-19: Therapeutic opportunities.新型冠状病毒肺炎中的淋巴细胞减少症：治疗机会。
Cell Biol Int. 2020 Sep;44(9):1792-1797. doi: 10.1002/cbin.11403. Epub 2020 Jun 3.
3
Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.主动疗法联合被动免疫疗法可能对对抗新冠病毒有效。
Clin Transl Sci. 2020 Sep;13(5):835-837. doi: 10.1111/cts.12816. Epub 2020 Jun 26.
4
Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient.对一名重症COVID-19患者进行白细胞介素-7同情用药的免疫监测。
Cell Mol Immunol. 2020 Sep;17(9):1001-1003. doi: 10.1038/s41423-020-0516-6. Epub 2020 Jul 29.
5
Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.2019年冠状病毒病的免疫学特征：T细胞功能耗竭与细胞因子风暴
J Clin Immunol. 2020 Oct;40(7):974-976. doi: 10.1007/s10875-020-00824-4. Epub 2020 Jul 10.
6
Cell-Free Therapies: Novel Approaches for COVID-19.无细胞疗法：治疗新冠肺炎的新方法。
Front Immunol. 2020 Sep 18;11:583017. doi: 10.3389/fimmu.2020.583017. eCollection 2020.
7
Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.SARS-CoV-2 感染患者外周血淋巴细胞反应和细胞因子谱的纵向特征。
EBioMedicine. 2020 May;55:102763. doi: 10.1016/j.ebiom.2020.102763. Epub 2020 Apr 18.
8
Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.2019冠状病毒病（COVID-19）与免疫参与性癌症治疗
JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.
9
COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies.新型冠状病毒肺炎：冠状病毒复制、发病机制及治疗策略
Cleve Clin J Med. 2020 Jun;87(6):321-327. doi: 10.3949/ccjm.87a.20047. Epub 2020 May 4.
10
Immunotherapies for COVID-19: lessons learned from sepsis.新冠病毒病的免疫疗法：脓毒症的经验教训
Lancet Respir Med. 2020 Oct;8(10):946-949. doi: 10.1016/S2213-2600(20)30217-4. Epub 2020 Apr 28.

引用本文的文献

1
Long COVID and the kidney.长期新冠与肾脏
Nat Rev Nephrol. 2025 Sep 4. doi: 10.1038/s41581-025-00997-4.
2
Sepsis: the evolution of molecular pathogenesis concepts and clinical management.脓毒症：分子发病机制概念的演变与临床管理
MedComm (2020). 2025 Feb 23;6(3):e70109. doi: 10.1002/mco2.70109. eCollection 2025 Mar.
3
A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19.一项关于IL-7用于新冠重症患者的随机、双盲、安慰剂对照试验。

本文引用的文献

1
Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction.对新冠病毒疾病（COVID-19）患者的尸检显示，肺部出现弥漫性肺泡损伤，伴有严重的毛细血管充血，肺部及其他器官呈现出多样化的表现，提示存在血管功能障碍。
Histopathology. 2020 Aug;77(2):198-209. doi: 10.1111/his.14134. Epub 2020 Jul 5.
2
The many faces of the anti-COVID immune response.抗新冠病毒免疫反应的多面性。
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20200678.
3
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
JCI Insight. 2025 Feb 4;10(6):e189150. doi: 10.1172/jci.insight.189150.
4
Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy.通过白细胞介素-7细胞因子疗法恢复CD8 T细胞动力学，使免疫检查点阻断在T淋巴细胞减少症中发挥疗效。
Front Immunol. 2024 Dec 16;15:1477171. doi: 10.3389/fimmu.2024.1477171. eCollection 2024.
5
Defining the correlates of lymphopenia and independent predictors of poor clinical outcome in adults hospitalized with COVID-19 in Australia.定义在澳大利亚因 COVID-19 住院的成年人中与淋巴细胞减少相关的因素和不良临床结局的独立预测因素。
Sci Rep. 2024 May 15;14(1):11102. doi: 10.1038/s41598-024-61729-5.
6
Harnessing the Power of IL-7 to Boost T Cell Immunity in Experimental and Clinical Immunotherapies.利用白细胞介素-7的力量增强实验性和临床免疫疗法中的T细胞免疫。
Immune Netw. 2024 Feb 15;24(1):e9. doi: 10.4110/in.2024.24.e9. eCollection 2024 Feb.
7
COVID-19 immune signatures in Uganda persist in HIV co-infection and diverge by pandemic phase.乌干达的 COVID-19 免疫特征在 HIV 合并感染中持续存在，并在大流行阶段出现差异。
Nat Commun. 2024 Feb 17;15(1):1475. doi: 10.1038/s41467-024-45204-3.
8
Immune dysregulation in sepsis: experiences, lessons and perspectives.脓毒症中的免疫失调：经验、教训与展望。
Cell Death Discov. 2023 Dec 19;9(1):465. doi: 10.1038/s41420-023-01766-7.
9
Improving thymus implantation for congenital athymia with interleukin-7.利用白细胞介素-7改善先天性无胸腺症的胸腺植入。
Clin Transl Immunology. 2023 Nov 22;12(11):e1475. doi: 10.1002/cti2.1475. eCollection 2023.
10
Host Response Changes and Their Association with Mortality in COVID-19 Patients with Lymphopenia.COVID-19 患者伴淋巴细胞减少症的宿主反应变化及其与死亡率的关系。
Am J Respir Crit Care Med. 2024 Feb 15;209(4):402-416. doi: 10.1164/rccm.202305-0890OC.
《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
4
Flip the coin: IL-7 and IL-7R in health and disease.翻转硬币：IL-7 和 IL-7R 在健康与疾病中的作用。
Nat Immunol. 2019 Dec;20(12):1584-1593. doi: 10.1038/s41590-019-0479-x. Epub 2019 Nov 19.
5
Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.白细胞介素-7 可恢复脓毒性休克中的淋巴细胞：IRIS-7 随机临床试验。
JCI Insight. 2018 Mar 8;3(5):98960. doi: 10.1172/jci.insight.98960.
6
Harnessing the biology of IL-7 for therapeutic application.利用 IL-7 的生物学特性进行治疗应用。
Nat Rev Immunol. 2011 May;11(5):330-42. doi: 10.1038/nri2970.